Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

KIDNEY CANCER

Disagreement in risk groups for metastatic renal cancer

Nature Reviews Urology volume 16, pages 332–333 (2019)Cite this article

Subjects

In patients with metastatic renal cell carcinoma, risk stratification according to the Memorial Sloan Kettering Cancer Center or the International Metastatic Renal Cell Carcinoma Database Consortium classification systems is a crucial part of clinical assessment and essential for guiding management. New research has now demonstrated that disagreement in risk-group classification is common and prognostically relevant.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Motzer, R. J. et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289–296 (2002).

    Article  CAS  Google Scholar 

  2. Heng, D. Y. C. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27, 5794–5799 (2009).

    Article  CAS  Google Scholar 

  3. Ljungberg, B. et al. EAU guidelines: renal cell carcinoma. uroweb http://uroweb.org/guideline/renal-cell-carcinoma (2019).

  4. Harrell, F. E. Problems caused by categorizing continuous variables. Vanderbilt University http://biostat.mc.vanderbilt.edu/wiki/Main/CatContinuous (2019).

  5. Noe, A. et al. Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. World J. Urol. 34, 1067–1072 (2016).

    Article  CAS  Google Scholar 

  6. Okita, K. et al. Impact of disagreement between two risk group models on prognosis in patients with metastatic renal cell carcinoma. Clin. Genitourin. Cancer https://doi.org/10.1016/j.clgc.2019.01.006 (2019).

    Article  PubMed  Google Scholar 

  7. Méjean, A. et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N. Engl. J. Med. 379, 417–427 (2018).

    Article  Google Scholar 

  8. Heng, D. Y. C. et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur. Urol. 66, 704–710 (2014).

    Article  Google Scholar 

  9. Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).

    Article  CAS  Google Scholar 

  10. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK

    Tobias Klatte

  2. Department of Surgery, University of Cambridge, Cambridge, UK

    Tobias Klatte & Grant D. Stewart

  3. Department of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

    Grant D. Stewart

Authors
  1. Tobias Klatte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Grant D. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tobias Klatte.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klatte, T., Stewart, G.D. Disagreement in risk groups for metastatic renal cancer. Nat Rev Urol 16, 332–333 (2019). https://doi.org/10.1038/s41585-019-0174-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-019-0174-6

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing